I'm Bill Brough and this is Kidney Cancer News. As we span the globe with stories of interest of families dealing with kidney cancer as well as medical professionals, this month we'll hear from Dr. Tim Eisen, one of the presenters at our most recent kidney cancer symposium in Chicago. We'll also take a look at the latest issue of kidney cancer journal and we have news of an important development in vaccine research, too. This month's edition of our print publication, Kidney Cancer Journal, Volume 10, No. 2 for 2012, features an important article on locally recurrent renal cancer, update on surgical interventions and prognosis. The late father of a deceased patient sponsored the work of the International Kidney Cancer Working Group, funded by the Kidney Cancer Association. This is a project that was in process for more than a decade. And a paper has been published in the Journal of Urology, improvement in overall survival of patients with advanced renal cell carcinoma, prognostic factor trend analysis from an international data set of clinical trials. You can read an abstract of this paper online at kidneycancer.org. IMADIX Biotechnologies, a biopharmaceutical company developing a rationally designed therapeutic vaccine active against cancer, has announced that it has completed patient recruitment to the Pivotal Phase III trial, evaluating its lead cancer vaccine IMA-901 for renal cell carcinoma. The trial has completed patient inclusion. It's expected that around 345 patients will be randomized across 10 countries in the U.S. and Europe. The first overall survival results are expected during the first half of 2014. For complete details on these and other stories, point your web browser to kidneycancer.org. Look for the pressroom link on the homepage. Now Dr. Tim Eisen kicks off the first in a series of reports from the recent International Kidney Cancer Symposium in Chicago. Both of you can view both presentations and abstracts from this meeting online at kidneycancersymposium.com. Sure, it's a pleasure. Thank you very much for asking me to do this. I'm a medical oncologist and I work in Cambridge where I'm the professor of medical oncology and I specialize in kidney cancer and lung cancer there and I also help run the clinical research side of our operation in Cambridge. So I've been working in kidney cancer now for several decades, two decades, and so I was involved with the initial developments, particularly of seraphonib and then some of the other drugs involved. Yes, I'm presenting a summary if you like and my view of the data that will affect the choice of first line treatment recommendations for patients. So I think there are a number of things that I'd like to cover in this. The first is that we've had a generation of agents, sonitinib, seraphonib, pisoponib, which are very similar to each other, what we call multi-targeted tyrosine kinase inhibitors. They target angiogenesis, new blood vessel formation which is very important in kidney cancer and they do it by hitting a receptor called VEGF-R2 and another number of other receptors. So I think they're more similar than initially we first thought. So we have very effective ways of controlling the kidney cancer with these agents for between nine and 12 months nowadays with the existing first line agents and the data that I'm reviewing at this conference is comparing two of those agents, sonitinib and pisoponib. And the bottom line is that in effectiveness terms, they are pretty similar. We couldn't see any statistically significant difference between them in a large study. And those data are presented by Bob Mox's data originally, presented by Kimmelo Porter at this conference. And then the other data I'm thinking about are with what I would call the second generation agents. So these are agents which are also similar to sonitinib, seraphonib, but they are more potent at hitting the key target and they are much less potent at hitting the targets we don't want to hit. So this is trying to give the idea that we have on-target things that we do want to do and off-target things that we don't want to do because they cause side effects without benefit. So the second generation of agents like tyvosinib and axitinib do cause side effects, but they cause on-target side effects. Things like high blood pressure, things like dysphonia, so you can get a hoarseness of the voice. Why that's on-target, we're not sure actually, but we do recognise it with all these agents and it correlates with how potent the agent is. And another thing sticking with the neck is that it can tone down the thyroid glands and hypothyroidism. We would consider all of those to be on-target effects. Examples of off-target effects are things like the skin rash, the hand foot syndrome that one gets, the diarrhea. We think those are off-target effects and another one which is important are liver function test abnormalities. So it's a question of balance between the side effects on the one hand and the effects on the other hand. Now when we're comparing data from the COMPAR study, which compares sunatinib, which is our existing standard of care with posopinib, which is a very similar drug, but used in a slightly different way, we find that in effectiveness terms there's really nothing between them. There's no statistical difference between them, but what there is is that patients seem to prefer the posopinib. So these are from a separate study called the Pisces study, where patients were given first one drug, then the other, and asked, which did you prefer? And neither the patient nor the doctor or the nurse knew what treatment the patient was getting. And 70% of the patients actually said they preferred posopinib compared to 20% saying they preferred sinusinib. So it's not 100-zero. Not everyone could choose between them. Most people could, but most people who could choose chose posopinib. We didn't see such a clear distinction in this COMPAR study. The purpose of the COMPAR study really was to check that you weren't swapping slightly more convenience and slightly fewer side effects for much less effectiveness, because I think that's a very difficult thing to square. So I would say that the bottom line of those data of importance today is that for most patients who have no liver problems, most patients would probably tolerate posopinib a bit better. It would be a bit more convenient. It would be a bit easier just to include it in your normal day. But I think that sinusinib is still a good drug and will still be better for several patients. Now, in certain parts of the world, you'll be able to get both drugs. In the part of the world I come from, you'll probably have to choose one or the other. So it may be more important data in one respect for me in that it helps me if I've got one shot, which shot do I offer the patient? So those are the data for today. There were also data for tomorrow, if you like, which I don't think are quite ready for prime time yet. The most advanced data are with a drug called tyvosinib. That's one of these second generation drugs, highly potent, highly specific. And that was compared with seraphonib, which was, I suppose, meant to be a drug which is easy to beat. Interestingly, we are much better at using seraphonib now. We recognize how to use it better. And so the results we're getting with seraphonib are really in exactly the same ballpark as the ones we're getting with seraphonib and tyvosinib. Interesting. I wouldn't say that's really established it as a first line of care at all. But in this study, tyvosinib was found to have a longer period of controlling the disease just over a year. It's the first time we've gone over the year mark for patients who've not had treatment before. And apart from these on-target effects, tyvosinib, with otherwise, pretty well tolerated. So we are getting hypertension. We are getting dysphonia, the changing of the voice. And we are getting toning down of the thyroid gland, all of which can be coped with, particularly the blood pressure, hypertension, and the thyroid gland. The dysphonia is trickier, actually. Although it sounds least serious, you can do less about it. And so for some patients, this is irritating. From my experience, it's not terribly irritating because it does happen with the other drugs as well. It tends to happen a bit more with these highly potent agents. So I think tyvosinib, you could say, well, it's a good drug. It should be available immediately. And in fact, the company has applied in the US to use it. And I think that would be a reasonable thing to do. So for somebody where quality of life is the number one consideration, and that's certainly my practice in the United Kingdom, there are quite a lot of patients. I would say tyvosinib is quite an attractive option. Other patients would feel efficacy and long-term survival are best. And we don't have those data reliably. In fact, interestingly, this study was mainly done in Eastern Europe. About 80% of patients came from Eastern European countries where the situation is very different from the US. Often no effective treatment is available outside a clinical trial. So in this trial, patients who got syraphanib were able to go on to tyvosinib after that drug failed, after syraphanib failed. But the same was not true, or the opposite was not true of patients who were allocated to tyvosinib. So after tyvosinib, most patients didn't get any other treatment. And that is one plausible explanation for why patients in the syraphanib arm going on to tyvosinib survived longer. So there is a significant difference there, but the data are early. And I think although the explanation I've given is plausible, just because it's plausible doesn't mean it's the right one. And I think we have to say that that is a caveat. My own feeling is that we can get a little bit bound up in detail in oncology. But I think this is quite an important distinction. I don't think we need another phase three trial to show that tyvosinib causes the same or helps the patient to live for as long as, shall we say, pysophanib or synitinib. Because I think that's going to take another three or four years. So I don't think we need another phase three study to compare survival. But I do think we need some data to show that the results we're getting for patients with tyvosinib are very, very similar to those we're getting with synitinib. So I think those are data for tomorrow. And the other data for tomorrow will, I think, be available sometime at GUASCO or ASCO next year are with oxytinib. So there is a first line study comparing oxytinib and other second generation with syraphanib, the drug that everyone wants to beat. Because it's meant to be the weakest of the available options. So I am expecting that we will have data for that drug as well. And I think those could be very persuasive data. And the importance of those would be that oxytinib could then be brought forward as a first line option. And I think that depending on how good those data are, that may well establish oxytinib as the agent of choice in the US, where it will be available first. In Western Europe, that would be much slower. So if you like, in my view, pysopinib has a period of time in the sun. But then there are new agents coming down the line. And the very last comment I want to make is that this is not the end of the story. I think we're very close to achieving all we're going to do with single agent tyrosine kinase inhibitors. But at this conference and other conferences, we've heard about new immunotherapies, new targets for drugs. We're going to get adjuvant therapy data, all of which may cause major benefits for patients in the years to come. And I think this is a really exciting prospect where hopefully we will be controlling disease for much longer. And of course, the golden chalice, if you like, is to get rid of it all together. I think there are two questions that everybody should ask their doctor when they get this sort of news. And the first is, can you tell me exactly what's wrong with me in my kidney and elsewhere in my body? Because that's going to determine what some of the treatment choices are. And I think that you do need to know these things. If, and I say if, not because I'm a particularly patronizing person, but because not everybody wants to make their own decisions. Some people want to listen to what the doctor, the nurse, the primary care physician suggests and do that. Other people want to be very involved in the decision. If you want to be very involved in the decision, then there are some basic things you need to know. And the first one is, where is my disease? What is my disease? And what other problems do I have? Those are all important because they will tell you, or they will tell your advisors, if you like, what treatment options you theoretically have. So for example, if the disease is limited to the kidney, surgery is going to be your best option. What kind of surgery? If you have disease in different parts of your body, is surgery really an option? No, probably not. It might be in a few cases, but usually not. So what treatments are available? Am I fit enough for them? What are the pros and cons of each of those options? So I think the second thing to ask is, what are my treatment options? Given what you just told me about, what's wrong with me? And tell me the pros and cons of each of them, please. And the last thing I would say is, there are very few decisions in kidney cancer which need to be made on the spur of the moment. Much, much better to take your time to reach a decision, not necessarily that you're happy with, it may not be a happy situation. But the important thing is to make the best decision for you. You must be satisfied with the decision and the reasons you've reached that decision. And if you're in two minds and you want to be guided, then ask for that guidance. And there are people who can guide you. The nurse specialists who are helping you are often extremely helpful at putting it in the right language rather than the sort of medical jargon that I and others often use. You need to understand the issues if you want to make the decisions. And most doctors and I think most nurses would like most patients to have a part in the decision even if it's not the whole part but a significant part. It just makes life much easier. You will do better in my view if you feel that the decision is something you can live with. Yes, the importance of asking questions is it's important at the time that you understand what you're told. If you don't understand what you're told, that doesn't mean you're thick. It means that you just don't understand what's been told. So we all break into jargon at times. Do please clarify things which are not clear. You are not wasting our time. It's one of the most important parts of medicine to make sure that you are communicating properly with the patient. And actually for me, it's much easier for somebody to say, hang on a second, I didn't understand that. Then for me to whitter on at length and then 10 minutes later, work out that actually stage A wasn't understood. So everything else that I've been going on about hasn't been understood either. So please, please don't feel embarrassed. We are there for you. You're not wasting our time. Much better to interrupt us. My name is Ulka Vaishampayan and I am the chair of the GU multidisciplinary team at Barbara and Carmina's Cancer Institute in Detroit, Michigan. This cancer center is an NCI designated comprehensive cancer center and affiliated with Wayne State University in Michigan as well. My practice and focus is genitourinary cancers, specifically within kidney cancer. My clinical practice is focused on kidney cancer along with the, as well as my clinical research is focused on kidney cancer as well. Patients get the awareness of not just new treatments because new treatments are frequently publicized all over the press, TV, newspapers, whatever, but they also realize or can, the information is transmitted about how we are fine tuning the existing therapies to serve them better. And the optimal treatment is still being decided for an individual patient. And we are really at the beginning of getting different genetic markers that may help us predict response. My presentation today is focusing within patient management issues of the disparities in treatment of kidney cancer. So even though we've improved outcomes tremendously in the last few years in kidney cancer, that in itself has caused a huge disparity gap to widen between the different people who don't have access to treatment, who have multiple other comorbid conditions that interfere with them receiving the optimal treatment and of course, race and socioeconomic factors as well as the biological factors within the cancer that induce all of these disparities. I think what patients should ask first of all is what is going to be the overall treatment plan? So not just the type of medication, but how are different modalities going to be integrated into their treatment? So probably the question needs to be, is am I a candidate for both surgery as well as receiving treatment by in terms of different targeted therapies or is it just going to be targeted therapies or some kind of systemic therapy first followed by the consideration of local therapies? So I think patients should be more aware in asking questions about consideration of multidisciplinary care. The other thing I think patients should become more aware of and be asking about is are there any clinical trials that are appropriate to my situation? Because typically what we find is that clinical trials in kidney cancers, especially in the last few years, have represented the most cutting edge type of treatment and has benefited majority of the patients who have enrolled on it. So I would say those would probably be the top two questions I would recommend patients ask. Sure, I did my training at the Cleveland Clinic for my residency and my fellowship in urologic oncology. I currently practice in Grand Rapids, Michigan at Spectrum Health, where I'm an associate professor at Michigan State University College of Human Medicine and also an investigator at the Van Andel Institute. So I'm a urologic oncologist, I'm a surgeon who serves as the research director for genital urinary cancers and is a lead in the clinical cancer program that we have at Spectrum Health. Patients with localized kidney cancer have a lot of options and I've presented evidence about all the various options that need to be considered. And what I tried to make very clear is that there's no one best treatment for all patients. There's a lot of things to consider and really the things that come into the fore are who's the patient and how many other medical problems are they encountering at the time of their diagnosis? What are the specifics of the tumor? How large is it? How complex in terms of deepness into the middle of the kidney? That impacts the success of various treatment options and the success of opportunities to spare the kidney. So those are important. And then the ultimate is the surgical factors and that can be impacted in great part by the center at which the person's receiving care, whose hands they're in in terms of receiving information regarding the types of options and also obviously what part of the country they live in because there are regional variations. We summarize some of the specifics and my task today was to talk about open partial nephrectomy. Well, partial nephrectomy is the largest number of patients will have this because the most patients with T1 renal cancer are candidates for it. Recent studies would show that at centers of excellence upwards of 90% of patients are able to keep their kidneys. If they have a small kidney cancer, four centimeters or less. And really for tumors even up to seven centimeters and select tumors that are larger, we are able to keep their kidneys. There's a variety of ways the surgery's done. One of them is with traditional open surgery. There's also minimally invasive options. So a laparoscopic approach to partial nephrectomy or a robot assisted laparoscopic approach. And again, there's varying techniques that can be used, but the important thing is to keep the kidney. And in the vast majority of patients with small renal masses, we can preserve the kidney. Absolutely. And so there's been a lot of discussion over the last decade about increasing use of partial nephrectomy, especially for smaller tumors. Some of these are slow growing. Some of them we even consider surveillance or watchful waiting in patients with significant medical problems. But for patients who are good surgical candidates and have small tumors, these are ones that we almost always can spare the kidney. So for smaller tumors, in almost every case, the kidney can be preserved. And so a partial nephrectomy is an option that enables a patient to keep their kidney and keep more of their kidney function. Even for medium-sized tumors, we can often do it. And so tumors that are even up to seven centimeters in size or bigger, partial nephrectomy may be an option. But what's the benefit to the patient? It's a real benefit in terms of kidney function. When you remove one kidney, as you'd expect, there's a significant change in kidney function. You might expect about 50% loss, but on average patients lose about 35% of their kidney function, because the one that stays in is able to take up some of the work for the lost kidney. But with partial nephrectomy, on average patients lose about 10 to 15% of kidney function. And so that's clearly less than with radical nephrectomy. For patients with perfectly normal kidney function, that may not be essential, but for many patients who are older or have diseases that can affect their kidney function, this is a very significant benefit to a kidney-sparing approach. So patients with hypertension, diabetes, kidney stone disease, coronary artery disease, smokers, or any of a number of other conditions that can affect the kidney, set up a situation where partial nephrectomy is clearly preferred. Patients with localized kidney cancer can expect great cancer outcomes if they have appropriate treatment. They can rest assured that cancer can be treated well. So the other thing they really wanna ask is, is there a chance to spare my kidney? And what does this physician or the surgeon feel are the chances that they can preserve the kidney? If they hear that their tumor is not amenable to a kidney-sparing approach, they might wanna check with that surgeon whether other surgeons would agree with that assessment that their kidney is not able to be salvaged because there's clearly some variability in practice patterns for small renal masses, right? So one essential question for a new patient to ask is, is a partial nephrectomy an option for me given the size of my tumor and the location of my tumor? If the answer's yes, that's good for their long-term outcome. If the answer's no, they might wanna double check and know that this is indeed the case that their kidney's gonna have to be removed, right? So second opinions are reasonably common for this disease because again, multimodality care is important. This is a disease where experts who are experienced in all the various stages of disease from early disease to locally advanced disease to metastatic disease are more comfortable with management and the different types of options that are available. The other thing to consider is that they're minimally invasive approaches, they're traditional surgical approaches and for patients who are not as good candidates, there are non-surgical alternatives. And so centers that have all of these techniques at their disposal can provide patients with a full spectrum of options. And the best possible care in any individual situation. I think it's important for patients who are newly diagnosed to get as much information as they can. The Kidney Cancer Association has wonderful resources available on the web and there are a number of written resources that are helpful as well. Absolutely, to know that you're not alone, that there's thousands of people across this country who have been in this situation before and through organizations such as the Kidney Cancer Association, you're able to get linked into patients, loved ones and providers who can really help you through with your condition.


Hi, I'm MC3 Weston Jones, and welcome back to another episode of Seas Stories aboard the mighty USS Jason Dunham, DDG 109. Right now we're topping off the tanks with our brothers and sisters in the French Navy aboard the FS Somme, and we have the Danish Navy frigate Absalon taking on fuel as well. We even have officers in the Polish Navy steering the ship. That's four partner nations coming together as a team to carry out this awesome evolution. And that's what Baltops is all about.


And I would go from that cafe to a jazz bar and from the jazz bar would go for a walk along the beach Right, right try to like we walk to like the quiet end of the beach where it's all you know in shadow and stuff And it's kind of romantic because it's good here the waves lapping and see the city lights and stuff And then I try to make out whether that was the game plan So in the beginning this date was a little lumpy and go on this date And I'd realize I got the timing all wrong was supposed to be a two-hour date We met at 8 p.m. And on a school night. I wasn't at school of course at this point in time But I call it a school night. So we're out there and you know We're a dinner for one hour and 20 minutes and then the bar for an hour and then it's already 10 20 And we both have to go to work in the morning.  So I refined it piece by piece and it ended up with a date They got really really good results Became a system and I could just repeat that system that same first date over and over and over So to give you an idea as I as I refine this date here with the statistics because I love my numbers after One of these dates and we'd end on a make-out after this date 91 percent agreed to dinner and move it my place for a second date Yes, read into that dinner in a movie at my place of those who would have them for a dinner in a movie at my place 89% of those dates would end in sex Now I'll tell you something that date structure is not awesome I've by by by watching clients that I've worked with over the years Evolved their own dating first dates Wow, there is so much more than you can do with a date than that kind of boring series of events But by systemized by creating a system that I could repeat I Could get the results and I could get consistent results over and over and over again I didn't have to think anymore. Where am I gonna go? What am I gonna do on this date? What's gonna happen crap? And have to do that any more You see Who would be surprised if someone came up to me today? Imagine one of you came up to me He said Damian, you know, I didn't know you're about your business in Australia. Yeah, tell me about it. How's it going? And I said it's going good and You said to me Cool, how many how many how many clients you usually work with a month? I'm not sure a couple few He said awesome, you know, how many you know, how how how when you run an event How many guys generally come to an event of yours are quite a few. Yeah, how many I'm not sure on the exact numbers Would you expect my business is gonna go well in the future? No, of course not so obvious when it's business. It's not so obvious when Stating pick up. We don't think how important that is But I do want to make a note not everything can be systemized I do want to make this clear If I'm out in this date, I cannot have the same conversation with every single girl You can't systemize that Because at the end of the day, you still have to be able to be charming. You cannot script that stuff You're not script. How are you gonna make a girl laugh? You're not script. How are you gonna build rapport? These are skill sets that you need to build But the overall process is something that you can systemize You can imagine if I sit down with a client With someone who's interested to sign up with me someone gives me a call and they say Damian. I'd love to work with you Cool. Let's have a chat. Let's have a have a coffee. I sit down with them Do you think that I sit down with these people these guys and just and just think to myself? well, I'll just kind of sit here and I'll be cool and answer any question. It's got and hopefully I'll get a sale Think that's how it's done No, it's what I do is I understand I need to take that person through a journey If you have who who is bought a car before or a TV or something that are really excited about yes Awesome when you went to buy that. Did you not want that salesperson to get you excited about that product?  I Know when I sit down with a client Well, I need to the first thing I need to do is I need to make them I need to laugh with them I need a tea I need to be a bit playful and joke around with them Why because that relaxes them laughing releases tension and they chill out and when they relax and they laugh with me They're more open to me So when I then go next to start asking about them and their lives and where they're struggling with they're more open to sharing with me And I have to I know it was part of my system I have to be genuinely interested to learn about them because we'll only open up to people who are genuinely interested in us So as you can see I have to go on a journey from there. What am I going to do? I'm going to talk about well This is what I do and this is how this is exactly going to help the area. We're struggling with most and And so on and so forth. There's a system that I follow. Okay, who is in control of that interaction? Do you think at all times? Yeah, in this case me someone comes to me they're interested about me and what I do in this case on the salesman Yeah, absolutely, and the same should be the case for every interaction that you guys have with women You should be the one who's in control you should have in your minds a system That you follow Let me give you an idea of a system a system could work like this You can approach a girl and the first thing you're gonna do is teaser and then you're gonna build rapport You know teaser again, and then you're gonna sexually escalate and you can ask for a number You can write this system down if you like it's a system I'm not saying this is the only way to attract women because that'd be crap But this is a system and it's probably ten times better than anything you guys are doing right now Because I one thing I know is most guys have no strategy at all So a strategy is better than no strategy, but a strategy that's yours that you've worked on That's the best strategy of all, but imagine this is my perfect strategy for a second I can walk up to a girl and can be an interaction with her and the first thing I do is approach and then I know I know in my head Ah, this has to be fun That's all my focus is just be playful just have fun here make this enjoyable make this engaging and Once just laugh once this card of chuckle the bit together right and that's a skill set I've worked on it's a skills that you all need to work on once. I've done that. I know in my head Ah now I have to actually learn about her Now is when I actually have to try to build some rapport get who she is what she wants what makes her tick Make her make her make her know that I get where she's coming from it's about building rapport and we do this and often A rapport based conversation is a bit heavy So once we've done that I'm gonna make it light-hearted again I'm gonna change teasing playfulness and teasing playfulness is very easy to then segue into being sexual sexual escalation Now I'm not going into how this all happens because that's not the nature of this talk You can come and chat to me afterwards at any time about anything to do with dating and relationships, but here's the thing knowing this Knowing this means it doesn't matter what emotional state.  So yes, it's very hard So the less thinking that your brain needs to do in an interaction or on a date or at any other time The better prepared you are for when you're intimidated for when you're tired when you've had a bad day Because when you meet the woman that you want to be with Not just the woman that you want to shag if you happen to cross paths with the woman Who's absolutely right for you that you'd actually like to seriously date make a part of your life You don't want to be too tired to be able to think clearly You don't want to be too intimidated to do anything good with it and have her pass you by If you've got a system you've got something to lean on you're starting to rely on you got something that you can trust We'll get the job done in summary guys. There's three things that you absolutely have to do number one You've got to measure everything I Kid you not Okay, if you run a business if you want to get better with women it is the same thing you must Measure it sounds dumb. Just keep like a spreadsheet Maybe six metrics that really matter to you seven metrics write it down And then and then every and then and what you do is you work out what you reckon you could easily make an improvement on You know if you think to yourself well look I approach every ten girls I approach six girls reject me seven girls reject me That's ridiculous Then focus all your energy. What could I do that would change it? What could I do that would improve the odds there and Then focus that whole week just go out approach ten twenty girls Changing that just that thing Did it make it better did it make it worse if it makes an improvement you hold on to that bad boy You test something new the next week That's how it's done. So you've got a test possible. So there is absolutely no end of really good information I mean this weekend you are gonna hear some really awesome stuff I've met some of the speakers and dating and pick up that are gonna be at this event. I've heard all of them before There's some really awesome stuff You've got to test it out like Socrates said already you've got action is where it's out If you don't take action and learn from that action nothing is ever ever gonna change and once once you've worked out what works You systemize it you create a system out of it so that you don't have to reinvent the wheel over and over and over again Which is what most of us do most of us jump into every interaction with a girl And we have to think about every part of that interaction over and over and over again And then we get lumpy results. We get unpredictability. We keep changing everything. We don't know what works and we don't know what doesn't work So guys, let me let me open up this stage to some questions We know that I've seen some guys writing some questions down I don't know if we want to ask the guys themselves or go off the pads of paper. I'll leave that up to Steve All right We have a question here that says does it not get boring or less special when you systematize a First date Yes, it absolutely does. Well, it doesn't get less special Here's the thing that happens every interaction that you have right every interaction you have if the girl herself is boring and Plenty are You shouldn't be on a date with her The excitement of an interaction with a girl is not where you go or the journey you take her on It's the interaction you have with her. It's how her humor is. It's when you build rapport with her Is there something about her that's fascinating to you? That's the stuff that's exciting one thing that I experienced with most guys is we never put enough weight on that stuff We think of it as she's hot. Okay, I got to try to make something happen As opposed to she's hot great That's the first step is she also a cool chick great now I'd like to go on a date with her so yes if you are with girls who you just with because they're attractive that is Going to get real boring real quickly, but if it's if it's a girl who's genuinely fascinating to you It just takes a load off and allows you actually appreciate what's happening Okay, how long did it take you to develop your dating system? Yeah, good question Can I just ask a qualifier there when you say dating system? What do you mean exactly? Just kind of like what you just kind of walked us through like your personal one that you use on a daily basis Yeah, yeah, yeah, sure. So I put that together I put that together, you know, I spent about two hours kind of just putting together what I thought would be a good date After about five dates. I would have said I was about 90% of the way there If that gives you any any feedback didn't take long so then what's the end goal is it to Sleep with a lot of women or is it just to have the ability to sleep with a lot of women? Or is it to find someone that you really want or and do that quickly or not make a mistake? What's the end goal? Yeah, actually, that's a really good question. I'm actually really happy you asked that Coaching he's also the founder of the school of attraction an NLP practitioner. Let's all welcome Damian Dica What's up, man? All right, plump them together into a system and Then you follow that system you make it as simple as possible, but no simpler You know in shadow and stuff and it's kind of romantic because it's good You hear the waves lapping and see the city lights and stuff and then I try to make out with that was the game plan So in the beginning this date was a lumpy and go on comes to me They're interested about me and what I do in this case on the salesman. Yeah, absolutely And this is a system and it's probably ten times better than anything you guys are doing right now because I one thing I know is most guys have no strategy at all so a strategy is better than no strategy Cool, it's nice to meet you got to go back to my my girlfriends now That's that's a that's a sort of a very quick snappy rundown of a woman's difficulty in dating It's women suffer just as much if not more than men with dating relationships You guys may be surprised with that but wow the The pain that the women go through is no more or less than what I deal with with guys all the time


Nick Saban has heard the rumblings, especially from David Pollock during last year's national championship. Georgia, obviously, you've seen in the past couple of seasons now, really, they've taken hold of college football. They did an unbelievable job. The SEC now belongs to Georgia and Kirby Smart. After back-to-back national championships, they can certainly say they own the SEC. But a scorned Nick Saban is not the type of guy to stay down the wall. His Alabama crimson tide this year has a stacked roster on both sides of the ball, a roster that leads the nation in blue chip ratio. Blue chip ratio basically looks at how many four- and five-star recruits you've landed versus the number of two- and three-star recruits you've landed. This stat is very good at predicting who's going to be competing for the national championship. This year, it's Alabama that has the best blue chip ratio. The only question mark for them coming into the season was at the quarterback position. But after Jalen Milroy's dominant performance in week one, it certainly looks like he's the guy. And if Milroy can repeat or at least play similar to the way he played in week one, it certainly looks like Alabama will be making their way back to the college who will play off after being left out last season.


Sorry, sorry. I'm Nushe, I'm 21 years old and I come from India. Perfect. I think I'm going to be a student. Forget about me, forget about me. The first memory was, I think, the math camp. So I remember it was the first day and all of us had turned up, you know, in the morning. My favourite subject right now would be program valuation, which we're doing. It's very interesting and I feel like I'm learning incredibly many new things. My dream job would be to be a researcher in health economics and because that also comes with a professorship, I wouldn't mind that either because I really like teaching people as well.


Hello everyone welcome to options with Doug streaming live daily on book map discord and the book map YouTube channel at 1 30 p.m. Eastern time before I get started I need to go through the disclosures general disclosure all book map limited materials information and presentations are for educational purposes only and should not be considered specific investment advice nor recommendations risk disclosure trading futures equities and options involves substantial risk of loss and is not suitable for all investors past performance is not necessarily indicative of future results the focus of my presentation and the focus of the options dash Doug chat channel and discord is options order flow the impact of options markets on stocks and futures and the influence of market maker hedging flow on price action I have a two-step process for trading and the first is planning and I use positional analysis I look at how traders and market makers are positioned in the options market and how those positions changed from day to day to develop a thesis regarding the expected trading range and volatility for the day as well as a directional bias and the second step in my process is execution and I look at real-time order flow and book map and real-time market maker hedging flow and spot gamma hero to confirm my thesis and for setups for entries and exits and just to be clear I will be talking about setups in an underlying asset like the S&P 500 futures or Apple stock or Tesla stock and those setups can be taken any number of ways with stock shares of stock futures contracts or options contracts and again my my thesis my planning my analysis is based on the options market but the setups can be taken any way you choose and questions and comments are welcome and I will be watching the options dash Doug chat channel and discord and the chat in YouTube for your questions and comments so please post your questions and comments and I'll do my best answer all right what I want to cover today my agenda for today first of all go over news items economic data events and earnings for today and for the rest of the week and then I'll go through my positional analysis then our view a few key setups from the morning the S&P 500 NASDAQ and then a few stocks and then we'll take a look at the live market and see if we can see any setups or see what's happening in the live market right let's get started so first of all news items today there was there was some news that came out this morning and let's just take a look at we'll take a look at the live market here let's go to the S&P 500 and there was a slight reaction to the data this morning first of all at 945 a.m. manufacturing PMI data came out that was lower than expected less than 50 indicating contraction and then services PMI PMI came out better than expected and that was greater than 50 indicating expansion so data came out at 945 and at 10 a.m. minor reaction all right for the rest of the week the big event is tomorrow and that is the FOMC minutes that will be released at 2 p.m. Eastern time and that will be at the halfway point of my session tomorrow so we'll we'll stop whatever we're doing and watch the watch the futures at 2 p.m. and then Nvidia reports after the market closes tomorrow and then Thursday GDP comes out at 8 30 a.m. Eastern time and then finally on Friday PCE data and durable goods come out at 8 30 a.m. Eastern time and then Michigan consumer sentiment at 10 a.m. all right so let's start with positional analysis now so that was the news news items for today in the rest of the week so in the morning session actually before I go under this chart let's take a look at a larger time frame so I'm gonna go take a look at SPX and this is a 30-day one hour chart for SPX just showing price and key level so let me point out the levels on this chart so first of all with a dash purple line I have the lower and upper edge of the expected move for the week and then this dash blue line is showing the lower and upper edge the expected move for the day and note that SPX is trading below the lower edge the expected move for the day and let me point out some spot gamma levels now these horizontal dark red lines these are provided to spot gamma subscribers for a variety of platforms here we're looking at a thinkorswim chart so I'm going to point out the key daily levels that I follow first of all there's the put wall at 4,000 that's the strike with largest net negative gamma that can be expected to act as support and hello JEC glad you're here so there is the put wall at 4,000 and then is the next level up is the absolute gamma strike at 4,150 that's the strike with largest absolute gamma and then just above that is the volatility trigger as JEC points out SPX is now trading below the volatility trigger and the volatility trigger is spot gamma is proprietary gamma flip level below that level market makers position on the gamma curve is a negative and negative gamma environment market makers have to trade with price to hedge their delta exposure and that tends to increase or enhance volatility when market makers are trading with price and there was some discussion some to questions and discord from this morning about positive and negative gamma and I really don't assign that much of a directional edge to positive gamma or negative gamma the market can move both ways in a negative gamma environment and a positive gamma environment and now I think spot gamma does assign a little bit of a bearish edge to index market trading below the volatility trigger and and positive above the volatility trigger and the volatility trigger again is spot gamma is proprietary gamma flip level negative gamma below and positive gamma above in a positive gamma environment market makers have to trade against price and that tends to subdue volatility so that's the main thing that I look at regarding the volatility trigger and and positive and negative gamma and then finally the call wall is up at forty three hundred that's the strike with the largest net positive gamma that can be expected to act as resistance so those are the spot gamma proprietary daily levels as well as the upper and lower edge of the expected move for the day and the week all right let's take a look at another think or swim chart just so we can focus on the levels and this is a think or swim chart one day one minute showing the levels that are in play for today and primarily again as the lower edge the expected move for the day as well as the volatility trigger so now SPX is trading below the volatility trigger and presumably has shifted to a negative gamma environment and by the way spy is already at the beginning of the day was already trading in a negative gamma environment we'll look at that in more detail in a couple of minutes right so let's take a look at book map now and in the morning session that was very very quiet with the S&P 500 trading between spy 417 and 418 so let me point out my columns on this chart and I'm I have my own cloud notes here these are spot gamma cloud notes these are mine the C levels and I'm showing key spy levels and that is the 418 volatility trigger and notice how many times that acted as resistance today and this just shows how key the spy levels are to the S&P 500 whether you're looking at spy itself or ES futures in this ratio the spy to ES ratio changes a little bit every day I have a think script that calculates it automatically all right so again in the morning session 418 volatility trigger resistance and the 417 level was support until finally breaking over around just after 1230 all right so those are the levels are in play and now it looks like maybe the 416 415 level for spy are in play and then here is the lower edge of the expected move for the day as well as the 4170 volatility trigger that was also noted as support in the spot gamma am founder's note and we'll look at setups in a few minutes all right so that's the S&P 500 let's talk about the NASDAQ now and for the NASDAQ pretty similar price action let's just take a look at a QQQ chart you have to rearrange this a little bit so this is QQQ a one-day one-minute chart and think or swim showing the round number levels as well as the spot gamma levels so the level spot gamma level and play for today is this 335 l3 level and that is also the absolute gamma strike for QQQ 335 so a key level for QQQ and similar to the S&P 500 trade in the morning was in a narrow range between QQQ 336 and 337 until it broke lower about the same time the S&P 500 did all right so let's go take a look at book map now and a book map I for NQ I still I have my cloud notes levels again so there's the 337 level that acted as resistance and the 336 support and now the NASDAQ is also trading below the lower edge the expected move for the day so price broke below or and then that acted as resistance so now price is trading below the 335 absolute gamma strike so again very important to keep track of the ETF levels on your futures charts all right so that is the those are the primary indices that I follow the S&P 500 the NASDAQ there were just a few a couple of shifts levels basically for SPX no shifts in levels for spy no shifts in levels I'm talking about the volatility trigger put wall call wall in absolute gamma strike all those levels remained the same from yesterday so let's take a look at the absolute gamma levels and we'll start with SPX so for SPX the put wall remains at 4,000 this chart is showing positive gamma or call gamma above the zero line with the orange bars and put gamma or negative gamma below the zero line with the blue bars and this is the strike with the largest net negative gamma that can be expected to act as support and then the absolute gamma strike at 4,150 strike with largest absolute gamma and then the the call wall is at 4,300 strike with largest absolute or net positive gamma although there is more more call gamma orange bars larger at the 4,200 strike all right so that is the SPX all the levels remain the same let's take a look at spy and for spy again the levels remain the same volatility trigger at 4,18 absolute gamma strike at 4,20 and that appears to be the center of the universe for spy right now and the call wall up a couple of points at 4,22 and the put wall remains at 400 so the range for spy for 400 floor and 4,22 ceiling and that was expected to act as resistance today according to spot gamma all right let's take a look at NDX before I do that I'm gonna need to refresh this page let's go to NDX and for NDX the center of the universe is the 13,850 strike and that is the absolute gamma strike as well as the call wall and the volatility trigger shifted higher up to 13,175 and that is not actually shown on this chart and then QQQ so that was one one of the two shifts in levels for today for these NDX products and that finally QQQ take a look at this zoom in just a bit so for QQQ the volatility trigger also shifted higher from 334 to 338 so here's the volatility trigger and for QQQ 335 is the absolute gamma strike and the put wall remains at 327 oops right here no not a lot of gamma but this is taking the difference between the put gamma and the call call gamma so that net negative gamma is there at 327 and then the call wall remains at 340 or let's take a look at one other thing while we're on this page we'll go to the Vana model I'm going to take a look at SPX and I like to look at this chart every day because it gives me a sense of how market makers may have to hedge so what this is showing is market makers delta notional or delta exposure on the vertical axis and how it changes with price shown on the horizontal axis and the gray curve is showing how market makers delta notional changes with changes in price and that is the this line again is showing delta delta change with price only and what this is showing is if price increases market makers delta notional will increase and they'll have to sell futures and that's typical of a positive gamma environment and then this purple curve adds implied volatility to the equation and that is showing how market makers delta notional will change with changes in price and implied volatility and that's the Vana effect the change in delta with a change in implied volatility and this curve is showing as a price increases market makers may have less delta notional to hedge than predicted by the delta only curve and then on the other hand as price decreases and implied volatility increases they will have more delta notional to hedge so as price decreases in a negative gamma environment they'll have to sell futures with price to hedge their delta exposure so let's take a look and see where SPX is trading now so remember the last time we looked SPX was below the below the volatility trigger at 4170 and also spy was below the volatility trigger at 418 so right now SPX is trading around 4162 so somewhere around here where I'm holding my cursor this vertical line so this is showing as price decreases market makers delta notional will increase and they'll have to sell futures and that tends to enhance volatility and when they're trading with price on the other hand if price starts to increase and implied volatility drops market makers delta notional will drop and they will have they can buy back some of their short futures so this this is how this works both ways in a negative gamma environment so that this will provide in the case of price increasing a tailwind price up to a certain point and then market makers will have to start selling futures again and let's just see how this has shifted the last couple days and just to one thing to keep in mind is market makers gamma notional for SPX is still positive but it has decreased over the last three days so let's go back a couple of days so there's a more positive gamma environment slightly less negative gamma environment and then again a slightly less negative gamma environment still positive for SPX alright so let's take a look at those numbers so what I'm talking about is this gamma notional there's another measurement of this spot gamma gamma index this is for SPX spy Ndx and QQ QQ QQ QQ QQ this is market makers position at the beginning of the day and this is showing that again gamma notional is positive for SPX although less positive than yesterday so it did shift down and for spy it is more negative than yesterday and then for QQ QQ it actually shifted it's still negative but not as negative as yesterday so a shift down in SPX and spy and shift higher but still negative for QQ QQ alright so take profit in YouTube ask why is hero gamma positive and Vanna negative so I'm not quite sure I understand your question we'll take a look at a hero in just a minute so I know that at least earlier today that hero was was positive was that's a delta that we're looking at with with hero so when when hero line is rising market traders are taking positive delta positions and Vanna is really what we're looking at is market makers position on the gamma curve whether that's positive or negative and Vanna is just again the change in delta with a change in implied volatility and it helps us to predict how market makers may be hedging alright let's let's move on now so that is the that's the information that goes into my positional analysis for the indices based on this I was looking for a range day today directional bias neutral at no shifts in levels there was really not enough to you know assign a directional edge one one way or another and then finally for volatility I was looking for moderate volatility more than the last couple days since gamma notional is shifting for more positive to either less positive or negative all right let's take a look at some setups so I'm going to start with with hero here and this is for the S&P 500 combined signal so this is what take profit is asking about so first of all this chart is from spot gamma spot gamma heroes showing price with the white line hero the hero signal hedging impact of real-time options H I RO and this is showing a combined signal for the S&P 500 for SPX spy XSP and ES futures and again this is hedging pressure or hedging flow so this is showing for the combined signal and it's really SPX spy and ES futures it is positive let's take a look at the individual components of the signal so first of all let's take a look at SPX and I'm looking for the SPX signal there it is so remember the total signal was about positive 1.7 billion so SPX positive so traders have been it looks like taking positive delta positions in SPX positive 450 million spy that's negative 189 million negative and then ES futures very positive 1.5 billion positive to get the total signal all right so let's zoom in on this so really as far as trading setups options traders in the S&P 500 were not helpful this morning they were maybe early in the morning remember when early in the morning the S&P 500 was trading in a very narrow range between 417 spy 417 and 418 and this was really just supporting longs with hero rising you know that traders are taking positive delta positions and market makers are buying futures to hedge those so in this case taking these long long set up some pullbacks or that they trend a fade trades favored longs but you know that there were good trades short and long between 418 and 417 all right so let's go take a look at book map let's go back to the S&P 500 I'm gonna zoom in on the morning session expand this just a little bit so this is the morning range very narrow between 417 and 418 to spy levels and again with hero rising somewhat favoring longs and I would say that order flow supported the same with cumulative volume delta increasing that shown by the the dark blue line and then also stop orders by stop orders shown by the rising orange yellow line then on the other hand it looks like the larger traders with iceberg orders had the right idea they were fading this move higher so they were selling as the S&P 500 approach the 418 volatility trigger so there is for example an execution of 1000 contracts it looks like three transactions those are those are iceberg orders that large traders use to hide their size and there's 1606 there's another one 1402 so larger traders were fading that move while options traders were were buying all right so that's the morning setup range day fades both short at the 418 level long first one at the 417 level then higher highs and then price broke lower and I was actually making launch so I did I did not see this let's go back and take a look at hero and see if there was any any clue for this final move lower and not really other than hero leveled off some time later so traders stopped taking positive delta positions but that was after price already started to move lower let's just see what traders were doing first of all we'll break out puts and calls so it looks like call buyers are still more aggressive than put buyers I'm looking at the number over on the right side here that's 3.8 billion positive versus minus 1.9 billion negative so that is showing that traders are buying calls and buying puts all right let's take a look at zero DTE and see if that provides any additional insight and no not really so that is showing just trades options trades that were today's expiration let's take a look at the total expirations this is showing all trades all expirations right so not a not a lot of clue for a hero today other than really kind of supporting the long fades up in the in the range day this morning all right let's take a look at Nasdaq now so this is similar to the S&P 500 showing a combined signal of NDX and QQQ so let's zoom in on this and there's I think more clarity here first of all let's zoom in on the morning so briefly hero supporting longs up until about 10 a.m. rising hero line traders are taking positive delta positions up until again about 10 a.m. and then hero starts to move lower it looks like price chopped around for quite a while let's go take a look at book map for Nasdaq I'm going to zoom in on the on the morning session here and just like the ES trading at a narrow range between two ETF levels 336 and 337 and then after 10 a.m. we saw that hero was trending lower fading favoring shorts as NQ made a series of lower highs until finally reversed and let's over a little bit until finally breaking lower and breaking below that 336 level about 1230 so that's the Nasdaq and let's go so if you're using hero is kind of a one of the signals primary signal for trading remember heroes rising up until about 10 a.m. so supporting longs up until 10 a.m. up to the 337 level and then supporting a short at the 337 level so it looks like the the best trade was probably to buy a put by the 337 put although on a low volatility range day I generally don't I would if I buy a put I'm looking for big movement all right so that is the that's the Nasdaq let's take a look at a few stocks and then we'll come back and take a look at the live market for stock I want to take a look at his Amazon let's go take a look at hero and we'll see the call buyers were driving price higher in Amazon separate outputs and calls I'm going to zoom in on this so up until about noon so traders were buying calls show them on the rising orange line and they were also buying puts call buyers were winning and then help to dry price higher when traders buy calls market makers sell calls and they have to buy stock to hedge their delta exposure and that can drive a price higher so that's Amazon and the next one is meta total signal so first of all notice meta here this hero signal and that is showing a weak hero signal what this is showing is that the hero signal for today is the weakest that it has been in the last 30 days and that may be difficult to see that's a light gray on this black background showing the range within the last 30 days that entire length of the slider and so it is the low end of the last 30 days and then the colored portion shows the range of the hero signal in the last five days and this is the hero signal for today is also within that range and it's you know just basically at the low end so we know that the hero signal for meta was weak today so that's what I was looking at and now let's go take a look at hero for meta zoom in on this and this is what I was looking at it in the morning so note the call wall also the key gamma strike at 250 and meta jumped right up to that let's zoom in on this just a bit so what I saw this morning was pretty much lack luster options trades as price zoomed up to that call wall level and then this alert fired off that meta had breached the call wall and that typically call wall is expected to act as resistance so that got my attention so now notice that hero starts to shift lower just a couple minutes later let's go take a look at bookbump so meta has been up and down so what I'm looking at and this is this was just a clear setup from this morning and again remember kind of lackluster options trades straight up to the call wall resistance level and then let's zoom in some more note the shift in order flow at the at the call wall look at all the pink volume dots so by sweep show them a very small green dots up to the 250 call wall resistance level and then the aggressive sellers come in you can tell that with the large pink volume dots those are market sell orders traders selling that 250 level so a short set up there in meta and another one let's take a look at Nvidia let's go back and take a look at hero because there's meta really hero supporting and you know the way I see this more short setups let's go to Nvidia and at video I also see this as confirming shorts so let's zoom in on the morning session so a couple things to note here first this looks like a somewhat of a divergence so hero starts falling before price falls then his price increases again somewhat lackluster trade up to a certain point and a couple of large block orders shown by those vertical lines drives price up for another short as hero continues to fall right so let's go take a look at book map that with this line and video makes a series of lower highs then breaks this wedge pattern whoops tool pulls back gives another opportunity for short as hero oscillates up and down but order flow definitely negative there notice all the pink dots aggressive sellers alright so that's Nvidia take a look at Tesla and then we'll go to the live market and let me know if you have any stocks that you want me to take a look at any other stocks than the ones that I've looked at alright here's Tesla let's take a look at hero and as usual there's a very strong correlation between hedging flow and price action for Tesla and then the morning the move up was was driven by call buyers shown by the rising orange line and note the number here so in the morning up until about 11 positive 144 million versus minus 49 the input so traders call buyers were winning 144 to minus 49 and you could just tell that by looking at the strong correlation between the price action and call buyers right so let's go take a look at book map and there's the strong move up in the morning in Tesla as traders were buying calls right now the price starts to roll over somewhere between 1045 and 1115 and let's see what impact options traders had on that alright so notice that around 1115 traders stop buying calls they start selling calls orange line rises and price stops rising it starts falling and continues down so now the total call signal for the day the net is minus 38 so net for the day they are actually selling calls buying calls in the morning they stop or around 1110 1115 start selling calls and price moves lower all right again let me know if you have any stocks that you wanted me to take a look at otherwise we'll take a look at the broad market so the only thing I can discern from this is that so the total signal for hero is still positive but starting to trend lower let's take a look at book map take a look at order flowing book map go back to the S&P 500 and note the iceberg orders continue to be negative and this is it can only we'll take a look at Palantir I don't have that in book map but we'll take a look at Palantir with hero in just a minute all right so this is the S&P 500 I think one of the key takeaways from today are the large traders with iceberg orders and note this number now this is the cumulative for the session and I I start my session actually this is so this is MBO data so my session started around 7 a.m. when I opened book map so that is accumulated iceberg orders from about 7 a.m. Eastern time and that's 23,000 minus 23,000 around 550 23,549 right now that is quite large I don't think I've seen a number that large and quite sometimes so large traders are in there aggressively selling with iceberg orders they used to hide their size very interesting and also stops that number is also negative it about minus 4,000 cumulative volume Delta is still positive and that's actually accumulated from when I get backfield data I believe I backfield data goes back to the open yesterday evening so now the S&P 500 ES is trading down below the SPX 4150 absolute gamma strike that was noted as the second level of support in the spot gamma am founders noted a more substantial level of support than the 4170 level and price continues lowered notice now the first of all this 417 level did act as resistance sort of price never reached that level and then the 416 level acted as resistance price sliced right through the spy 415 level and as now down at the 414 level I love this this really helps my long-term position right so let's take a look at we'll go to hero take a look at Palantir and then we'll take a look at the NASDAQ so there you go Kenobi there's Palantir very strong correlation between options trades hedging flow and price action and call buyers are in charge shown by the strong correlation between the orange line and price action and note that when traders stop buying calls start selling calls price starts to move lower let's take a look at NASDAQ and overall a negative signal today for NDX and QQQ and again started to move lower just after 10 a.m. Eastern time trending lower and now price is really moving lower let's go take a look at that book map for NASDAQ notice again price is trading below the lower edge the expected move for the day shown by the dashed blue line so while I've been talking today there were a good short setups first of all at the lower edge of the expected move for the day and then the 335 key gamma strike absolute gamma strike for QQQ acted as resistance and then it looks like temporarily the 333 acted as support alright so RJ points out the VIX is up 10% let's check on that so the VIX made it up to 19 19.31 now seems to be rolling over just a little bit now for NASDAQ it looks like some larger traders are coming in and starting to buy with iceberg orders 175 contracts 145 contracts so NDX is still above its volatility trigger spy and SPX are below their volatility triggers and then QQQ is also below alright so RJ says great divergence with NAS so are you talking about hero let's see so it looks like yes so good spot so it looks like now options traders starting to take positive delta positions and Q reversed higher at the 333 level and also again large traders were coming in with iceberg orders let's take one last look at the S&P 500 then we'll call it a day so it doesn't look like a strong a balance and the S&P 500 but it looks like larger traders were buying with iceberg orders and maybe so let's go take a look at hero for for the S&P 500 so options traders still playing the bounce in NASDAQ S&P 500 not really heroes still trending lower and potentially just setting up a pullback to take a short alright my time is up turned out to be an interesting afternoon remember tomorrow the FOMC minutes come out at 2 p.m. during my session so we'll go through positional analysis and then at 2 p.m. start looking at the futures for setups alright thank you everyone thanks for your questions or comments and thanks for watching I'll see you tomorrow bye


Hi, my name's Genevieve Bell and I'm the director of the 3a Institute here at the Australian National University We're committed to building a new applied science. That's all about managing cyber physical systems from a human point of view if you're a risk-taker if You're interested in a transformational experience if you care about intellectual leadership. You should come join us Hello, I'm Professor Brian Schmidt vice-chancellor here at the Australia National University I'm excited to introduce the incredibly important 3a Institute the first of our ANU innovation institutes The issues of today's increasingly AI enabled world are complex and challenging The 3a Institute is tackling these issues in a very concrete and practical way I am personally excited to be supporting the work by Professor Genevieve Bell and her team to bring to life a new applied science to manage the machines It is a reflection of our commitment to driving innovation at the university both as an educational incubator and an ideas accelerator


The Kaiser Shipyards in Richmond, California, the SS Benjamin Warner Last Liberty Ship to be built on the Pacific Coast stands ready for launching. A miniature statue of liberty presented to the record-breaking shipbuilders of Richmond is unveiled in the presence of Henry Kaiser, one of America's foremost production experts. The new vessel, Last of the Liberty Ship Class, slides down the ways. The Kaiser Shipyards will now manufacture the new, larger, and faster victory ships for the allies. The SS Benjamin Warner takes its place in the great fleet of American-built merchant vessels. At Chongqing in China, Generalissimo Chang Kai-shek meets a plane arriving from Russia. Aboard is Henry Wallace, Vice President of the United States, here as the personal representative of President Roosevelt. At the Service Men's Club, Wallace is welcomed by Red Cross workers. On this important tour of the Far East, he takes time off for a volleyball game with American soldiers. With Madam Chang Kai-shek, Vice President Wallace visits an orphanage of a China now in the eighth year of its war with Japan. Chinese youngsters greet the visitor from far off America. At Chang Kai-shek's summer residence, over 150 guests attend an official banquet given by the Generalissimo and Madam Chang in Wallace's honor. Chang proposes a toast to the victory of the United Nations. Hanwood's New Hampshire delegates from 44 allied and associate countries arrive for the opening of the United Nations Monetary and Financial Conference. Invited by President Roosevelt to the first major world financial meeting since the London Conference of 1933, they will work in the seclusion of this white mountain's resort. Kang Xikong, one of China's representatives with Secretary and Mrs. Henry Morgenthau. United States Treasury Secretary Morgenthau heads the American delegation. On the opening day in his role of Acting Conference President, he addresses the meeting to be discussed our plans for the stabilization of world currencies. All agreements must be ratified by the governing bodies of the nations involved before becoming effective. Delegates to this Monetary and Financial Conference pose on the hotel lawn. These meetings are designed to promote trade in the post-war world and to create a foundation for lasting peace. At Washington's National Airport, a giant army transport plane comes in from Algiers, bearing a famous visitor on his first American trip. Arriving for conferences of extreme importance with President Roosevelt is Charles de Gaulle, leader of the Fighting French. Seventeen guns salute is given for the distinguished visitor who is welcomed with high military honors. The French National Committee led by de Gaulle has been accepted as the authority for civil administration of liberated France. General Marshall, Admiral King, and General Arnold join in saluting France's national anthem, The Marseillais. De Gaulle renews an old acquaintance ship with General George Marshall, United States Army Chief of Staff. Admiral Ernest King, Commander-in-Chief of the American Fleet, General H.H. Arnold, Commander of the Army Air Forces, and President Roosevelt's two military aides, General Watson and Admiral Brown, also greet the nation's foremost visitor. Leaves for the White House and a meeting with President Roosevelt, which is greatly to increase agreement and understanding between America and the new France. The Fighting French leader is cordially welcomed by the President, his daughter Anne Bottiger, and Secretary of State Cordell Hull. Secretary James Forrest Dahl and Harold Icke's Secretary of the Interior join in this official greeting. Next day in Arlington Cemetery, General de Gaulle pays homage at the grave of the unknown soldier, an American who fought and died on the soil of France in the last war. Today, in Normandy, Americans and Frenchmen again fight side by side. From Washington, de Gaulle arrives at New York City Hall. The people of Manhattan give him a tremendous ovation. In the RCA building, France's leader sees America's largest city. Including his visit, which has reaffirmed the ancient bonds of friendship between America and France, General Charles de Gaulle speaks to the people of the United States. To be on American soil and again to have met President Roosevelt, we have talked and I found, thus we have a common understanding of the grave problems facing us. I take this opportunity to thank the American people for the wonderful effort they have made to win this war. Today, us in 1918, your American boys are fighting side by side with the French soldiers. Together, we are marching on the road to Berlin, to Tokyo, to a final victory.